164
Participants
Start Date
December 17, 2020
Primary Completion Date
June 17, 2023
Study Completion Date
July 14, 2023
SLS-002
Intranasal racemic ketamine hydrochloride 90 milligrams (mg)
Placebo
Intranasal placebo
Standard of care
Standard of care treatment will be determined by the treating physician(s) based on clinical judgement and practice guidelines
Intranasal device
Device to deliver intranasal solution
Seelos Investigational Site, Buffalo
Seelos Investigational Site, Gaithersburg
Seelos Investigational Site, Morgantown
Seelos Investigational Site, Decatur
Seelos Investigational Site, Atlanta
Seelos Investigational Site, Miami Lakes
Seelos Investigational Site, Hollywood
Seelos Investigational Site, Miramar
Seelos Investigational Site, Miami
Seelos Investigational Site, Oakland Park
Seelos Investigational Site, Flowood
Seelos Investigational Site, North Canton
Seelos Investigational Site, Cincinnati
Seelos Investigational Site, Springfield
Seelos Investigational Site, Richardson
Seelos Investigational Site, DeSoto
Seelos Investigational Site, Houston
Seelos Investigational Site, Salt Lake City
Seelos Investigational Site, Panorama City
Seelos Investigational Site, San Diego
Seelos Investigational Site, Orange
Seelos Therapeutics, Inc.
INDUSTRY